Results 131 to 140 of about 10,402 (207)

A phase II trial of decitabine, bortezomib and pegylated liposomal doxorubicin for the treatment of relapsed or refractory AML. [PDF]

Leuk Res Rep, 2023
Jonas BA, Potter LA, Galkin M, Tuscano JM.   +3 more
europepmc   +1 more source

Pegylated Liposomal Doxorubicin/Trastuzumab Regimen [PDF]

, 2020
openaire   +1 more source

Efficacy of regional cooling + oral dexamethasone for primary prevention of hand-foot syndrome associated with pegylated liposomal doxorubicin. [PDF]

Support Care Cancer, 2023
Nara K, Taguchi A, Yamamoto T, Tsuruga T, Tojima Y, Miyamoto Y, Tanikawa M, Sone K, Mori M, Takada T, Suzuki H, Osuga Y.   +11 more
europepmc   +1 more source

Cardiotoxicity of combined pegylated liposomal doxorubicin and bevacizumab therapy: a propensity-matched cohort study and disproportionality analysis. [PDF]

Cardiooncology
Hoeger CW, Choudhary A, Diaz ANR, Pinto T, Smalec S, Doladille C, Wadhera R, Shea M, Khadke S, Salem JE, Ganatra S, Asnani A.   +11 more
europepmc   +1 more source

Pegylated liposomal doxorubicin does not affect cardiac function in patients treated for gynecologic malignancies. [PDF]

Gynecol Oncol Rep
Levytska K, Naumann RW, Benfield MJ, Brown J, Casablanca Y, Lees B, Puechl AM, Crane EK.   +7 more
europepmc   +1 more source

Efficacy and toxicity of CLAG combined with pegylated liposomal doxorubicin in the treatment of refractory or relapsed acute myeloid leukemia. [PDF]

Cancer Med, 2023
Yao H, Zhang C, Tan X, Li J, Yin X, Deng X, Chen T, Rao J, Gao L, Kong P, Zhang X.   +10 more
europepmc   +1 more source

The Efficacy and Safety of Pegylated Liposomal Doxorubicin-Based Neoadjuvant Chemotherapy in Children With Osteosarcoma: A Retrospective Real-World Study. [PDF]

Cancer Innov
Wang G, Tang S, Chai L, Liang Y, Li T, Bi W, Feng C.   +6 more
europepmc   +1 more source

[Pegylated liposomal doxorubicin in ovarian cancer treatment].

Ginekologia polska, 2009
Ovarian cancer treatment after cytoreductive surgery is based solely on chemotherapy. Pegylated liposomal doxorubicin (PLD) is a cytotoxic agent of verified efficacy in the treatment of ovarian cancer and is may be used in the first and the following lines of chemotherapy.
openaire   +1 more source

Enhancing targeted delivery and efficacy of PEGylated liposomal doxorubicin with liposomal minoxidil: comprehensive in silico, in vitro, and in vivo tumor model studies. [PDF]

Drug Deliv
Mohammadzadeh V, Arabi L, Hosseinikhah SM, Mashreghi M, Kalalinia F, Mostajeran N, Zirak MR, Hadizadeh F, Nejabat M, Kamali H, Rahiman N, Jaafari MR.   +11 more
europepmc   +1 more source

Non-pegylated liposomal doxorubicin in older adjuvant early breast cancer patients: cardiac safety analysis and final results of the COLTONE study. [PDF]

Clin Exp Med, 2023
Coltelli L, Finale C, Musettini G, Fontana A, Barletta MT, Lucarini AR, Fabiani I, Scalese M, Bocci G, Masini LC, Soria G, Cupini S, Arrighi G, Barbara C, De Maio E, Salvadori B, Marini A, Pellino A, Stasi I, Emdin M, Giaconi S, Marcucci L, Allegrini G.   +22 more
europepmc   +1 more source